Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    16105050 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
Conditions: Type 2 Diabetes;   Microalbuminuria
Intervention: Drug: irbesartan

Indicates status has not been verified in more than two years